170487 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving receptors, cell surface antigens or cell surface determinants; Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3 MHC-molecules, e.g. HLA-molecules
Peptides and combination of peptides for use in immunotherapy against various tumors
#302Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#303Peptides and combination of peptides for use in immunotherapy against various tumors
#304NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
#305Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
#306PEPTIDES
#307Agents and methods to elicit anti-tumor immune response
#308RELAXIN1 derived peptides for use in immunotherapy against various tumors
#309Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
#310Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
#311Peptides and combination of peptides for use in immunotherapy against various tumors
#312NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
#313Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#314Methods and materials for reducing suppression of immune function
#315CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
#316IMMUNOLOGICAL TEST KIT FOR EVALUATING VACCINE EFFICACY AND STORAGE METHOD THEREOF
#317Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
#318Peptides and combination of peptides for use in immunotherapy against various tumors
#319Peptides and combination of peptides for use in immunotherapy against various tumors
#320Peptides and combination of peptides for use in immunotherapy against various tumors
#321Peptides and combination of peptides for use in immunotherapy against various tumors
#322METHODS FOR USING EXOSOMES TO MONITOR TRANSPLANTED ORGAN STATUS
#323Peptides and combination of peptides for use in immunotherapy against various tumors
#324Peptides and combination of peptides for use in immunotherapy against various tumors
#325Immunotherapy against melanoma and other cancers
#326Methods and systems for predicting alloreactivity in transplantation
#327METHOD OF SCREENING MHC MOLECULES
#328OBSTRUCTIVE SLEEP APNEA (OSA) BIOMARKER PANEL
#329Biomarkers for determining the clinical response to cell therapy
#330Peptides and combination of peptides for use in immunotherapy against various tumors
#331BIOMARKERS FOR PREDICTING DEGREE OF WEIGHT LOSS IN MALE SUBJECTS
#332Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
#333METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDES AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR
#334Peptides and combination of peptides for use in immunotherapy against various tumors
#335VACCINE COMPOSITIONS AND METHODS OF USE THEREOF
#336Peptides and combination of peptides for use in immunotherapy against various tumors
#337T cell receptors and peptides derived by mutations for the treatment of cancer
#338HLA-RESTRICTED EPITOPES ENCODED BY SOMATICALLY MUTATED GENES
#339Method of identifying human compatible T cell receptors specific for an antigenic target
#340NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS
#341COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS
#342IL-10-PRODUCING CD4+ T CELLS AND USES THEREOF
#343Reagents and methods for identifying, enriching, and/or expanding antigen-specific T cells
#344Methods of making and using soluble MHC molecules
#345Peptides and combination of peptides for use in immunotherapy against various tumors
#346NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
#347Peptides and combination of peptides for use in immunotherapy against various tumors
#348Peptides and combination of peptides for use in immunotherapy against various tumors
#349Peptides and combination of peptides for use in immunotherapy against various tumors
#350Minor histocompatibility antigens and uses thereof
#351Biomarkers useful in liver fibrosis diagnosis
#352Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
#353Methods and Devices for Detecting Diabetic Nephropathy and Associated Disorders
#354Tumor antigen peptide
#355Determining Antigen Recognition through Barcoding of MHC Multimers
#356Attribute sieving and profiling with sample enrichment by optimized pooling
#357Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
#358COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS
#359METHODS FOR DIAGNOSING AND TREATING CD1D RESTRICTED GAMMA/DELTA T CELL LYMPHOMAS
#360MHC-I restricted epitopes containing non-natural amino acid residues
#361Peptides and combination of peptides for use in immunotherapy against various tumors
#362Peptides and combination of peptides for use in immunotherapy against various tumors
#363NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
#364Immunotherapy against melanoma and other cancers
#365Cancer treatment and immune system regulation through FAT10 pathway inhibition
#366ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) BIOMARKER PROTEINS
#367Methods of selecting T cell receptors using affinity oligonucleotide conjugates
#368ANTI-MICA ANTIBODIES
#369Peptides and combination of peptides for use in immunotherapy against cancers
#370METHODS OF IDENTIFYING ANTIGENS FOR VACCINES
#371Methods for Predicting and Monitoring Cancer Patients' Response to Teatment by Measuring Myeloid Derived Suppressor Cells (MDSCs)
#372Uterine cancer treatments
#373METHOD FOR THE DETECTION OF ANTIGEN PRESENTATION
#374Reagents and methods for identifying, enriching, and/or expanding antigen-specific T cells
#375IDENTIFICATION OF T CELL TARGET ANTIGENS
#376Methods and kits for screening transplant recipients and candidates
#377METHODS FOR USING EXOSOMES TO MONITOR TRANSPLANTED ORGAN STATUS
#378IDENTIFICATION OF IMMUNOLOGICALLY PROTECTIVE NEO-EPITOPES FOR THE TREATMENT OF CANCERS
#379Immunological reagents and uses therefor
#380METHOD FOR PRODUCING AUTOLOGOUS TOLEROGENIC DENDRITIC CELLS (TOLDCS) WITH SPECIFIC ANTIGENS AND THEIR USE IN THE PREPARATION OF A MEDICAMENT USEFUL FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
#381Ligand discovery for T cell receptors
#382METHOD FOR MONITORING CATHEPSIN S INHIBITION
#383Method for treating melanoma
#384Methods and systems for predicting response to immunotherapies for treatment of cancer
#385Peptides and combination of peptides for use in immunotherapy against various tumors
#386COMPOSITIONS, KITS AND METHODS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS
#387Peptides and combination of peptides for use in immunotherapy against various tumors
#388Peptides and combination of peptides for use in immunotherapy against various tumors
#389Means and methods for breaking noncovalent binding interactions between molecules
#390NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS
#391METHODS AND COMPOSITIONS FOR TREATMENT OF MACROPHAGE-RELATED DISORDERS
#392Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides
#393Methods of diagnosing and treating tuberculosis
#394Methods of Detecting Alloantibodies Using HLA and Non-HLA Antigens
#395Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
#396Method for treating cancer with activated T cells
#397Method for identifying novel minor histocompatibility antigens
#398Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#399Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#400Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#401Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
#402Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#403Method for treating cancer with an activated T lymphocyte that selectively recognizes a cancer cell consisting of specific peptide
#404Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#405Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#406Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#407Pharmaceutical compositions containing beta-2 microglobulin and methods of treating autoimmune diseases
#408Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
#409Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
#410Identification of antigen epitopes and immune sequences recognizing the antigens
#411Isolated donor MHC-derived peptide and uses thereof
#412Biomarkers associated with schizophrenia
#413Neoantigen treatment prioritization using multivariate analysis based on: HLA genotype, self-similarity, similarity to known antigens, antigen expression levels and mutant allele frequency
#414Compositions and methods for screening T cells with antigens for specific populations
#415Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
#416Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
#417MHC class I associated peptides for prevention and treatment of hepatitis B virus infection
#418Enhancing T cell activation using altered MHC-peptide ligands
#419Lym-1 and Lym-2 targeted CAR cell immunotherapy
#420DETECTION AND TREATMENT OF CANCER
#421IDENTIFICATION OF LIGANDS AND THEIR USE
#422Agents and methods to elicit anti-tumor immune response
#423Peptides and combination of peptides for use in immunotherapy against various tumors
#424Peptides and combination of peptides for use in immunotherapy against various tumors
#425Peptides and combination of peptides for use in immunotherapy against various tumors
#426Peptides and combination of peptides for use in immunotherapy against various tumors
#427Peptides and combination of peptides for use in immunotherapy against various tumors
#428Peptides and combination of peptides for use in immunotherapy against various tumors
#429Peptides and combination of peptides for use in immunotherapy against various tumors
#430NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
#431Peptides and combination of peptides for use in immunotherapy against various tumors
#432CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
#433Methods and Devices for Detecting Kidney Damage
#434Treatment of inflammatory skin disease
#435HLA class I-expressing non-human animal
#436Methods of Detecting Antibodies Specific for Denatured HLA Antigens
#437SOLUBLE TCR MOLECULES AND METHODS OF USE
#438Method for the absolute quantification of naturally processed HLA-restricted cancer peptides
#439Method and Prognostic Kit for Monitoring Multiple Sclerosis (MS)
#440Atypical hemolytic uremic syndrome (AHUS) biomarker proteins
#441METHOD OF INHIBITING BINDING OR ACTIVITY OF MIF BY ADMINISTERING A MIF ANTAGONIST
#442Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
#443Methods and compositions for the diagnosis and treatment of cancer
#444Complexes of types of MHC class II that bind to collagen type II peptides and their use on diagnosis and treatment
#445COMPOSITIONS FOR OVARIAN CANCER ASSESSMENT HAVING IMPROVED SPECIFICTY
#446METHOD FOR THE DETECTION, PREPARATION AND DEPLETION OF CD4+ T LYMPHOCYTES
#447Identification of immunogenic mutant peptides using genomic, transcriptomic and proteomic information
#448Lymphocyte biomarkers for determining the clinical response to cell therapy
#449Methods for detecting peptide/MHC/TCR binding
#450MHC-I restricted epitopes containing non-natural amino acid residues
#451METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
#452COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS
#453Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
#454Methods and materials for reducing suppression of immune function
#455Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
#456Cancer treatment and immune system regulation through FAT10 pathway inhibition
#457Peptide MHCII tetramers to detect endogenous calnexin specific CD4 T cells
#458METHOD OF SCREENING MHC MOLECULES
#459Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex
#460Method for prediction of an immune response against mismatched human leukocyte antigens
#461Methods and Devices for Detecting Diabetic Nephropathy and Associated Disorders
#462Identification and analysis of fetal trophoblast cells in cervical mucus for prenatal diagnosis
#463Isolated cardiac stem cells and methods of their use
#464ANTI-CANCER VACCINES
#465MEANS AND METHODS FOR BREAKING NONCOVALENT BINDING INTERACTIONS BETWEEN MOLECULES
#466Methods of treating gastrointestinal sarcoma patients depending on their sB7H6 serum level
#467Method for identifying novel minor histocompatibility antigens
#468SPECIFIC REMOVAL OF ACTIVATED IMMUNE CELLS
#469Mica binding agents
#470Immunological reagents and uses therefor
#471CANCER PROGNOSTIC ASSAYS
#472PERSONALIZED CANCER VACCINES AND ADOPTIVE IMMUNE CELL THERAPIES
#473Compositions and methods for the detection of antibodies to native human leukocyte antigen
#474Comparative Ligand Mapping from MHC Positive Cells
#475BIOTINYLATED MHC COMPLEXES AND THEIR USES
#476Soluble TCR molecules and methods of use
#477Method for producing an examination reagent and kit for analysing a T-cell frequency
#478SEMA5B peptides and vaccines including the same
#479Biomarkers useful in liver fibrosis diagnosis
#480Epitope testing using soluble HLA
#481MHC-I restricted epitopes containing non-natural amino acid residues
#482Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
#483Therapeutic agent for malignant tumors expressing MHC class II
#484Methods and compositions for diagnosis and prognosis of renal injury and renal failure
#485Identification of T cell target antigens
#486Biomarkers for lymphoma
#487Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
#488THERAPEUTIC USE OF THE ß2m PROTEIN
#489Human sample matching system
#490COMPARATIVE LIGAND MAPPING FROM MHC CLASS I POSITIVE CELLS
#491COMPARATIVE LIGAND MAPPING FROM MHC POSITIVE CELLS
#492MHC peptide complexes and uses thereof in infectious diseases
#493ASSAY METHOD AND DEVICE
#494METHOD OF SCREENING MHC MOLECULES
#495Serum Markers Predicting Clinical Response to Anti-TNF Alpha Antibodies in Patients with Psoriatic Arthritis
#496ENHANCING T CELL ACTIVATION USING ALTERED MHC-PEPTIDE LIGANDS
#497COMPOSITIONS, KITS AND METHODS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS
#498Vaccine compositions and methods of use thereof
#499METHOD OF PRODUCING A SET OF MHC MOLECULES
#500Compartment-Specific Non-HLA Targets for Diagnosis and Prediction of Graft Outcome
#501MIF antagonists
#502BIOMARKERS FOR THE TREATMENT OF PSORIASIS
#503Compositions and methods of identifying tumor specific neoantigens
#504Agents and methods to elicit anti-tumor immune response
#505Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
#506Methods of detecting antibodies specific for denatured HLA antigens
#507MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
#508Compositions and methods for the detection of antibodies to native human leukocyte antigen
#509Tumor antigen peptide and use thereof
#510Methods and Devices for Detecting Kidney Transplant Rejection
#511Methods and systems for detecting MHC class I binding peptides
#512Devices for Detecting Renal Disorders
#513Methods and Devices for Detecting Kidney Damage
#514Methods and Devices for Detecting Diabetic Nephropathy and Associated Disorders
#515Computer Methods and Devices for Detecting Kidney Damage
#516Methods and devices for detecting obstructive uropathy and associated disorders
#517Methods and Devices for Detecting Glomerulonephritis and Associated Disorders
#518COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS
#519Method of inhibiting binding or activity of MIF by administering a MIF antagonist
#520Methods for use with BAFF antagonists
#521Treatment and prevention of inflammatory diseases and autoimmune diseases
#522Method for Identifying a MHC Class H-Dependent Tumor Associated T Helper Cell Antigen
#523Methods and kits for screening transplant recipients and candidates
#524MHC peptide complexes and uses thereof in infectious diseases
#525Biomarkers for Ovarian Cancer: B2 Microglobulin
#526NOVEL THYMIC CELLULAR POPULATIONS AND USES THEREOF
#527BIOMARKERS USEFUL IN LIVER FIBROSIS DIAGNOSIS
#528Biomarker for the Medicine and the Biology of the Reproduction
#529POTENTIATION OF CELLULAR IMMUNITY USING HISTONE DEACETYLASE (HDAC) INHIBITORS.
#530Method for Identifying a MHC Class II-Dependent Tumor-Associated T Helper Cell Antigen
#531Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients
#532Method of Producing a Set of MHC Molecules
#533Methods for selecting candidate peptides presented on the surface of cancer cells following their binding to MHC class I molecules
#534Quantitative microarray of intact glycolipid CD1d interaction and correlation with cell-based cytokine production
#535Methods and Compositions for Using MHC Class II Invariant Chain Polypeptide as a Receptor for Macrophage Migration Inhibitory Factor
#536METHODS FOR IDENTIFYING T-CELL EPITOPES ASSOCIATED WITH IMPAIRED PEPTIDE PROCESSING AND APPLICATIONS OF THE IDENTIFIED EPITOPES
#537Panel cell used for granulocyte antibody detection
#538SPECIFIC REMOVAL OF ACTIVATED IMMUNE CELLS
#539Compositions and methods for the prevention and treatment of autoimmune conditions
#540BETA2-microglobulin and C reactive protein (CRP) as biomarkers for peripheral artery disease
#541MULTIPLE MYELOMA AND AL AMYLOID IMMUNOTHERAPY TARGETING IMMUNOGLOBULIN LIGHT CHAINS AND USES THEREOF
#542METHODS OF USING MULTIVALENT MHC CLASS II-PEPTIDE CHIMERAS
#543HLA-E BINDING
#544Point-of-care mass spectrometer system
#545Method of Screening Mhc Molecules
#546Panel of biomarkers for peripheral arterial disease
#547Method for screening for compounds using MHC class II invariant chain polypeptide and macrophage migration inhibitory factor
#548Expression of HLA proteins on non human cells
#549Means and methods for breaking noncovalent binding interactions between molecules
#550Method to identify epitopes
#551Method for identifying and quantifying of tumuor-associated
#552Biotinylated MHC complexes and their uses
#553Method and kit for the early detection of impaired renal status
#554Binding polypeptides and uses thereof
#555Comparative ligand mapping from MHC positive cells
#556Modified soluble T cell receptor
#557Methods of identifying optimal variants of peptide epitopes
#558Epitope testing using soluble HLA
#559Multiplex vaccine
#560Non-invasive assessment of intra-amniotic environment
#561Analysis of MHC-peptide binding interactions
#562Prediction and assessment of immunogenicity
#563Analysis of MHC-peptide binding interactions
#564Methods
#565Method for diagnosing a predisposition of psychosis in a progeny
#566Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
#567CIS-interactions between MHC molecules and co-expressed proteins, related neurological and non-neurological disorders and related therapeutic/diagnostic utilities
#568Isolated T lymphocyte receptors specific for human autoantigens complexed with human MHC molecules and methods of making and using same
#569Compositions and methods related to a dimeric MHC class I and II-Like molecule (dsMHCI and dsMHCII)
#570MHC bridging system for detecting CTL-mediated lysis of antigen presenting cells
#571Phosphopeptide antigens associated with MHC molecules
#572Compositions and methods for modulating immune response
#573Soluble TCR molecules and methods of use
#574Method for determining embryo quality
#575Methods for the assessment and prognosis of sarcoidosis
#576Systems and methods for detecting analytes from captured single biological particles
#577Methods for detecting binding of peptide-MHC monomers to T cells